ISPC Market Analysis
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-329.050.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$2.7MMicro cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 3.34
- P/S (TTM)
- 2.64
- EV/EBITDA
- 0.43
Profitability & growth
- ROE (TTM)
- -895.0%
- Operating margin
- -1627.0%
- Revenue growth YoY
- -85.2%
- Dividend yield
- —
- Beta
- 1.63
Last earnings
Apr 1, 2026 · Reported $-6.66
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About iSpecimen Inc
Company profileiSpecimen, Inc. provides technology that connects life science researchers in need of human biofluids, tissues and living cells for their research with biospecimens available from healthcare provider organizations globally. The company is headquartered in Lexington, Massachusetts.
Classification
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 8 CABOT ROAD, WOBURN, MA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$2.7M
Shares outstanding$1.4M
52W high$103.20
52W low$1.77
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent